Laidlaw Begins Coverage on Senti Biosciences (NASDAQ:SNTI)
Laidlaw assumed coverage on shares of Senti Biosciences (NASDAQ:SNTI – Free Report) in a report released on Friday morning, Marketbeat reports. The firm issued a buy rating and a $5.00 price objective on the stock. Separately, Chardan Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Senti Biosciences in a […]
Laidlaw assumed coverage on shares of Senti Biosciences (NASDAQ:SNTI – Free Report) in a report released on Friday morning, Marketbeat reports. The firm issued a buy rating and a $5.00 price objective on the stock. Separately, Chardan Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Senti Biosciences in a […]
